WEIR monoclonal antibody contract
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The contract involves the development of strain-specific monoclonal antibodies targeted at influenza, aimed at creating alternative potency assays to support pandemic influenza vaccine development. This effort is led by the Food and Drug Administration and seeks to enhance the tools available for evaluating vaccine effectiveness against specific influenza strains. The contract is categorized under NAICS code 541714, which relates to research and development in biotechnology. The solicitation is currently in a forecast stage with no solicitation number provided yet, and details such as the place of performance and contracting officer remain undecided. Points of contact for the acquisition include the CBER Acquisition Liaison, whose email is provided, while the contracting officer’s information is pending. This contract represents a critical component in advancing influenza vaccine quality assurance through innovative assay solutions.
General Info
Agency
NAICS
Place of Performance
USSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
